Trial Profile
Nicotinic Receptors and Schizophrenia: Phase II
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs GTS 21 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- 15 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record..
- 01 Feb 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 29 Sep 2011 Actual initiation date (Jul 2011) added as reported by ClinicalTrials.gov.